|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0017262,
umls-concept:C0030705,
umls-concept:C0087111,
umls-concept:C0140080,
umls-concept:C0185117,
umls-concept:C0202220,
umls-concept:C0242957,
umls-concept:C0278488,
umls-concept:C0597357,
umls-concept:C0681842,
umls-concept:C0683598,
umls-concept:C2911684
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-11-25
|
|
pubmed:abstractText |
Her-2/neu and the insulin-like growth factor-1 receptor (IGF-1R) share common postreceptor-signaling pathways, and pre-clinical models have implicated IGF-1R-signaling in resistance to treatment with the anti-Her-2/neu antibody trastuzumab. The present analysis was performed to evaluate the clinical relevance of IGF-1R expression within the context of trastuzumab-based therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, IGF Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, erbB-2,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological,
http://linkedlifedata.com/resource/pubmed/chemical/trastuzumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0171-5216
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
132
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
9-18
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16184380-Adult,
pubmed-meshheading:16184380-Aged,
pubmed-meshheading:16184380-Aged, 80 and over,
pubmed-meshheading:16184380-Analysis of Variance,
pubmed-meshheading:16184380-Antibodies, Monoclonal,
pubmed-meshheading:16184380-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16184380-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16184380-Breast Neoplasms,
pubmed-meshheading:16184380-Disease-Free Survival,
pubmed-meshheading:16184380-Drug Resistance, Neoplasm,
pubmed-meshheading:16184380-Female,
pubmed-meshheading:16184380-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:16184380-Humans,
pubmed-meshheading:16184380-Immunohistochemistry,
pubmed-meshheading:16184380-Middle Aged,
pubmed-meshheading:16184380-Predictive Value of Tests,
pubmed-meshheading:16184380-Receptor, IGF Type 1,
pubmed-meshheading:16184380-Receptor, erbB-2,
pubmed-meshheading:16184380-Survival Analysis,
pubmed-meshheading:16184380-Treatment Outcome,
pubmed-meshheading:16184380-Tumor Markers, Biological,
pubmed-meshheading:16184380-Up-Regulation
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.
|
|
pubmed:affiliation |
Clinical Division of Oncology, Department of Medicine I, Medical University of Vienna, 18-20 Waehringer Guertel, 1090, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article
|
